Showcasing forays into the biology of tau, researchers at AD/PD reported news on tau’s transcriptional regulation, its bungling of synaptic vesicles, its sway over the epigenome, and even flashed an atomic structure.
Manufacturers of a therapy system called neuroAD, which combines transcranial magnetic stimulation with cognitive training, are applying for FDA marketing clearance.
Using torpedo-like DNA snippets to delete mRNAs from cells, scientists lowered the amount of ataxin-2 protein. This allayed disease in mouse models of two neurodegenerative disorders.
Congress has opposed the Trump administration’s request to cut NIH funding, agreeing on a $2 billion boost, with a $400 million bonus for Alzheimer’s research.
Found in familial and sporadic cases of ALS, mutations in the annexin A11 gene lead to elaborate protein clumps and seem to disrupt vesicular trafficking.
Even without this important sidekick at hand, scientists are forging ahead with efficacy trials of their first attempts at disease-modification in Parkinson’s
Preparing the whole mouse head—not just the dissected brain—lets researchers analyze the neural tissue outside the skull that connects the nose to the inner sanctum.